Brokerages Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $14.70

Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year […]